ESLA vs EVAX

Estrella Immunopharma, Inc. vs Evaxion A/S — Valuation Comparison 2026

ESLA

Biotechnology
Estrella Immunopharma, Inc.
Quality
3.1
out of 10
Value Trap
12
SAFE
Price
$1.14
Last close
Models
8/13
Active
VS

EVAX

Biotechnology
Evaxion A/S
Quality
1.9
out of 10
Value Trap
12
SAFE
Price
$4.10
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ESLA Fair ValueESLA Upside EVAX Fair ValueEVAX Upside
Bayesian DCF Intrinsic $0.32 -71.7% $1.09 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.01 -98.9% $0.18 -95.5%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $1.51 +35.0%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ESLA vs EVAX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ESLA vs EVAX — Which Stock Is More Undervalued?

ESLA scores higher with a 3.1/10 quality rating vs EVAX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Estrella Immunopharma, Inc. (ESLA) and Evaxion A/S (EVAX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ESLA currently trades at $1.14 with a QOC of 3.1/10, while EVAX trades at $4.10 with a QOC of 1.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).